Uso del PET-TC en la evaluación de la respuesta al tratamiento neoadyuvante en el cáncer de recto localmente avanzado, nueva herramienta, nuevas preguntas

Oliva Perez, Rodrigo; Lynn, Patricio B; Habr-Gama, Angelita.
Rev. argent. coloproctología ; 23(2): 99-102, jun. 2012. graf
Artículo en Español | LILACS | ID: lil-696298

Documentos relacionados

  1. p21 as a Predictor and Prognostic Indicator of Clinical Outcome in Rectal Cancer Patients.
  2. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
  3. Ultrasound/CT combined with serum CEA/CA19.9 in the diagnosis and prognosis of rectal cancer.
  4. [Treatment of localized rectal cancer in 2024].
  5. Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA.
  6. [Low Anterior Resection Syndrome - Diagnosis - Therapy - Prophylaxis].
  7. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
  8. Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients.
  9. [Palliative Treatment of Metastatic Rectal Cancer].
  10. [Resection of a left obturator lymph node recurrence five years five months after surgery for rectal cancer].